Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting

Biomarker research to provide deeper understanding of mechanism of
action, relationship between efficacy and adverse events

OXFORDSHIRE, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md.–(BUSINESS WIRE)–Immunocore Limited, a leading T cell receptor (TCR) biotechnology
company, will present new mechanism of action data in advanced uveal and
cutaneous melanoma from the tebentafusp clinical research programme at
the American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago on 3 June 2019. Tebentafusp (IMCgp100) is a novel bispecific
biologic T cell receptor therapy with an anti-CD3 immune-redirecting
effector function and specifically targets gp100, a lineage antigen
expressed in melanocytes and melanoma.

“At ASCO, we will present clinical and biomarker data from our lead
bispecific tebentafusp programme that provide insight into its mechanism
of action,” said David Berman, Head of Research and Development at
Immunocore.
“We believe these data will translate across our ImmTAC
platform and provide another step towards identifying which patient
populations benefit.”

Poster discussion/poster: Pharmacodynamic effect of IMCgp100 (TCR–CD3
bispecific) on peripheral cytokines and association with overall
survival in patients with advanced melanoma
(Abstract #9523, Poster
#94)

  • Highlighting new mechanism of action results for tebentafusp
    (IMCgp100), this poster will be presented by Mark Middleton, MD, Head,
    Department of Oncology, University of Oxford, on Monday 3 June,
    1:15-4:45 p.m. CDT in Hall A.
  • The poster will also be discussed by Sophie Piperno-Neumann, MD,
    Department of Medical Oncology, Institut Curie, in the Melanoma/Skin
    Cancers poster discussion session on Monday 3 June, 4:30-6:00 p.m. CDT
    in Room E451.

Poster: Relationship between clinical efficacy and AEs of IMCgp100, a
novel bispecific TCR–anti-CD3, in patients with advanced melanoma
(Abstract
#9530, Poster #101)

  • In a retrospective analysis, reporting the potential association of
    rash with overall survival and temporal association of key cytokines
    with cytokine mediated adverse events for tebentafusp (IMCgp100), this
    poster will be presented by Omid Hamid, MD, Chief of Translational
    Research and Immunotherapy and Director of Melanoma Therapeutics,
    Angeles Clinic, in the Melanoma/Skin Cancers poster session on Monday
    3 June, 1:15-4:45 p.m. CDT in Hall A.

Analyses presented at the meeting stemmed from a Phase 1 clinical trial
assessing the safety and tolerability of tebentafusp (NCT01211262).

About Tebentafusp

Tebentafusp is a novel bispecific biologic T cell redirection therapy
with an anti-CD3 immune-redirecting effector function that specifically
targets the melanoma associated antigen gp100. It is now in pivotal
studies for metastatic uveal melanoma. Tebentafusp has Fast Track
Designation and Orphan Drug Designation in the US and Promising
Innovative Medicine designation under the UK Early Access to Medicines
Scheme for metastatic uveal melanoma. For more information about
enrolling tebentafusp clinical trials for metastatic uveal melanoma,
please visit ClinicalTrials.gov
(NCT03070392).

About Immunocore

Immunocore is a leading T cell receptor (TCR) biotechnology company
working to create first-in-class biological therapies that have the
potential to transform patients’ lives. The Company’s primary
therapeutic focus is oncology and it also has programmes in infectious
and autoimmune diseases. Immunocore has a pipeline of proprietary and
partnered programmes in development and the lead tebentafusp is being
investigated in pivotal clinical studies as a treatment for patients
with metastatic uveal melanoma. Collaboration partners include
Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda
Gates Foundation. Immunocore is headquartered at Milton Park,
Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US.
The Company is privately held by a broad international investor base.
For more information, please visit www.immunocore.com.

Contacts

Immunocore
Louise Conlon, External Affairs and Brand
Communications Manager
T: +44 (0) 1235 438600
E: info@immunocore.com
Follow
on Twitter: @Immunocore

Syneos Health Communications
(Tebentafusp/IMCgp100)

Stephanie Bukantz
T: +973 477 1814
E:
ImmunocorePR@syneoshealth.com